A Novel Liposomal Bupivacaine Formulation to Produce Ultralong-Acting Analgesia

Abstract

This novel liposomal formulation had a favorable drug-to-phospholipid ratio and prolonged the duration of bupivacaine analgesia in a dose-dependent manner. If these results in healthy volunteers can be duplicated in the clinical setting, this formulation has the potential to significantly impact the management of pain.